First Trust Exchange-Traded Fund VI First Trust Nasdaq Pharmaceuticals ETF (FTXH) News

U.S. stock markets rebounded on the 19th, buoyed by a decline in long-term interest rates following intervention by the U.S. Treasury.

U.S. stocks rebounded. The Dow Jones Industrial Average closed up $119.65 at $53,463.05, while the Nasdaq Composite ended 41.38 points higher at 26,331.09. Markets rose after the open, supported by lower interest rates following the Treasury Department's announcement of an increase in long-term Treasury bond buybacks to provide liquidity support. Prices remained firm throughout the day, but the release of the minutes from the July Federal Open Market Committee (FOMC) meeting in the final stages of trading pointed to the necessity of further rate hikes if inflation fails to decelerate.

Fisco Japan5minutes ago

Eli Lilly in Deal With Amplitude to Develop Trans-amplifying RNA Vaccines

Seeking Alpha25minutes ago

Biotechs Hit a Post-pandemic High After MRNA Trial Win for Moderna, Merck

Seeking Alpha02:38

New CDC Director Says Vaccines Are 'Safe and Effective'

Seeking Alpha02:38

Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions

Benzinga02:31

Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva

Benzinga02:02

Pfizer Stock Rises Wednesday: What's Going On?

Benzinga01:56

Moderna Shorts Reportedly Suffer $5B Loss After Stock's Sudden Rise

Seeking Alpha01:20

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Benzinga01:10

Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade

Benzinga01:10

Investors Should Position For Humanoid Robot Boom—Here's A Picks-And-Shovels Play; First MRNA Cancer Vaccine Succeeds

Benzinga01:09

Why Is BioNTech Stock Surging on Wednesday?

Benzinga00:39

BioNTech's Rally on Moderna Trial Win Likely to Fade, Leerink Says

Seeking Alpha00:08

Dividend Stocks Continue to Climb as SCHD Eyes Ninth Straight Weekly Gain

Seeking AlphaAug 19 23:27

Moderna's Cancer Vaccine Win Is Merck's Story Too

BenzingaAug 19 23:12

Moderna Stock Jumps 150%, Best Day Ever On Cancer Vaccine Win

BenzingaAug 19 23:06

Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

BenzingaAug 19 22:08

Moderna’s stock price doubled as Merck & Co announced the success of Phase III trials for its mRNA cancer vaccine, marking a historic breakthrough in melanoma treatment.

Moderna and Merck & Co announced on Wednesday that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large-scale Phase III clinical trial. This marks the first successful Phase III trial for mRNA technology in the field of cancer treatment and represents a major breakthrough for personalized immunotherapy in the history of oncology.

wallstreetcnAug 19 21:33

Argus Research Maintains Buy on Amgen, Raises Price Target to $460

BenzingaAug 19 21:17 · Ratings

'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ

BenzingaAug 19 21:09